Imfinzi FDA Approval History
Reviewed by J.Stewart BPharm. Last updated on Apr 22, 2020.
FDA Approved: Yes (First approved May 1, 2017)
Brand name: Imfinzi
Generic name: durvalumab
Dosage form: Injection
Treatment for: Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small Cell Lung Cancer
Imfinzi (durvalumab) is a programmed death-ligand 1 (PD-L1) blocking antibody indicated:
- for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who:
- have disease progression during or following platinum-containing chemotherapy.
- have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum containing chemotherapy.
- for the treatment of adult patients with unresectable, Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
- in combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
Development Timeline for Imfinzi
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.